Search

everythinglearnresearchcommunity

for

Search:↓

Certain genetic variants in the androgen receptor are linked to higher PSA levels, potentially affecting prostate cancer screening outcomes.

Finasteride is safe for hair loss treatment and doesn't increase high-grade prostate cancer risk.

The document suggests that blocking sweat glands with antiperspirants might allow skin-generated hormones to be absorbed, possibly increasing breast and prostate cancer risk.

Early hair loss may increase the risk of prostate cancer, especially in African American men and those with frontal baldness.

Dutasteride may lower the chance of finding prostate cancer in men with enlarged prostates.

A protein called CBP is found in prostate cancer and can increase the effectiveness of certain prostate cancer treatments.

Men with male pattern baldness have a higher risk of dying from prostate cancer.

The document suggests more research is needed to understand the link between baldness and prostate cancer.

Baldness at age 40 is not linked to a higher risk of aggressive prostate cancer.

Men with early hair loss may have a higher risk of enlarged prostate and possibly prostate cancer due to shared hormonal factors.

Using a single PSA level to decide on a prostate biopsy is not effective; a more personalized approach considering various factors is recommended.

Early balding, especially frontal, increases prostate cancer risk; more research needed.

Higher DHT in male baldness may protect against prostate cancer.

Genetic differences within ethnic groups may affect prostate cancer treatment effectiveness.

Baldness, especially at the front, may lower the risk of testicular cancer by 31%, but its link to prostate cancer is unclear.

The ABI1 gene contributes to prostate cancer progression and treatment resistance.

Extracellular vesicles and androgen receptors may help identify prostate cancer resistance and reduce SARS-CoV-2 infection.

Dutasteride may help shrink prostate cancer tumors.

5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.

Finasteride may reduce prostate cancer spread by lowering certain enzyme levels.

Finasteride treats hair loss but may affect prostate cancer detection.

Dutasteride and finasteride have similar effects on prostate cancer risk in BPH patients.

Black ethnicity, prior PSA tests, enlarged prostate, and family history increase prostate cancer risk; Asian ethnicity, obesity, smoking, diabetes, and less sexual activity or no children decrease risk.

Saw palmetto supplements may reduce prostate cancer cell growth without being toxic.

Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.

Medications for BPH can have significant side effects, so understanding these risks is important for treatment decisions.

African American men with prostate cancer have more androgen receptor mutations, which may lead to more aggressive cancer compared to Caucasian American men.

5α-reductase inhibitors may help with prostate cancer but could increase the risk of severe tumors, so careful use is advised.

Age, race, family history, and certain genetic factors increase prostate cancer risk.

Physical activity, height, and smoking affect prostate cancer risk.